A big study testing the medicine Olumiant (baricitinib) has shown good results in children with severe hair loss. This study is a team effort with a company called Incyte. The study, called BRAVE-AA-PEDS, is in its final phase (phase III) and is the first and largest of its kind. It shows that teenagers in the study grew back almost all their scalp hair in one year. Also, 71% of the teenagers had successful hair regrowth. The improvements kept getting better over the 52 weeks. These results build on earlier findings from the same study that were shared in March at a big skin doctor meeting. A doctor from Yale School of Medicine, Dr. Brittany Craiglow, said these results are good news. She said that starting treatment early with baricitinib can help many people, both adults and teenagers, grow back a lot of their hair. In another part of the study, 80% of teenagers who had hair loss for less than two years and took a higher dose of baricitinib grew back their hair. For those who took a lower dose, 64.3% had successful hair regrowth. Lilly, the company that makes baricitinib, will share these results at a big skin doctor meeting in the fall. They also plan to share the final results from two other studies, BRAVE-AA1 and BRAVE-AA2. Baricitinib was first approved in the US for adults with severe hair loss in 2022. Now, these new findings suggest it could also help younger patients. Lilly plans to share these results with regulators to update the medicine’s label. Anabela Cardoso, a senior official at Lilly, said that if approved, baricitinib could offer a new and important treatment option for teenagers with hair loss.